Clinical Trials
2 trialsNCT02704858 2026-03-02
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT06357377 2026-01-14
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
Neonc Technologies, Inc.
Phase 1 Not yet recruiting